EyeGate Pharmaceuticals I...

35.30
0.00 (0.01%)
At close: Mar 28, 2025, 3:59 PM
35.48
0.50%
After-hours: Mar 28, 2025, 04:05 PM EDT

Company Description

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye.

The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees.

The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.

The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina.

The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

EyeGate Pharmaceuticals Inc.
EyeGate Pharmaceuticals Inc. logo
Country United States
IPO Date Feb 13, 2015
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Stephen From

Contact Details

Address:
271 Waverley Oaks Rd Ste 108
Waltham, MASSACHUSETTS
United States
Website http://www.eyegatepharma.com

Stock Details

Ticker Symbol EYEG
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001372514
CUSIP Number 30233M503
ISIN Number US30233M5031
Employer ID 00-0000000
SIC Code 2834

Key Executives

No executives data available.

Latest SEC Filings

Date Type Title
Mar 25, 2025 8-K Current Report
Mar 25, 2025 S-8 Filing
Mar 25, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 12, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 10, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 10, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 15, 2025 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SCHEDULE 13G Filing